Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.

Abstract:

:An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including those of the EU (under the Mutual Recognition Procedure), it is approved for the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. In several other countries, including the USA, it is approved for the treatment of motor fluctuations in patients with advanced PD. In adults with advanced PD, levodopa/carbidopa ES improved motor fluctuations, activities of daily living and health-related quality of life (HR-QOL) during short-term (12-week) treatment, with the beneficial effects on motor fluctuations largely sustained over the longer term (up to 7 years). Levodopa/carbidopa ES was generally well tolerated in this patient population, with adverse events (AEs) associated with aging, advanced PD-related comorbidities, the procedure/device or dopaminergic therapy. Its safety profile was comparable to that of oral levodopa/carbidopa with respect to non-procedure/device-associated AEs; most procedure/device-associated AEs were consistent in nature and incidence with medically recognised complications of the procedure in non-PD patients. Current evidence indicates that levodopa/carbidopa ES is an effective and generally well tolerated option for the treatment of motor fluctuations in patients with levodopa-responsive advanced PD who are not being effectively managed with non-invasive therapies.

journal_name

Drugs

journal_title

Drugs

authors

Hoy SM

doi

10.1007/s40265-019-01201-1

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

1709-1718

issue

15

eissn

0012-6667

issn

1179-1950

pii

10.1007/s40265-019-01201-1

journal_volume

79

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.

    abstract::Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-1057-0

    authors: Pereira MJ,Eriksson JW

    更新日期:2019-02-01 00:00:00

  • Renal protection in hypertensive patients: selection of antihypertensive therapy.

    abstract::Hypertension is common in chronic renal disease and is a risk factor for the faster progression of renal damage, and reduction of blood pressure (BP) is an efficient way of preventing or slowing the progression of this damage. International guidelines recommend lowering BP to 140/90 mm Hg or less in patients with unco...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565002-00005

    authors: Wenzel RR

    更新日期:2005-01-01 00:00:00

  • Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).

    abstract::Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345040-00002

    authors: Sandström E,Oberg B

    更新日期:1993-04-01 00:00:00

  • Suvorexant: first global approval.

    abstract::Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0294-5

    authors: Yang LP

    更新日期:2014-10-01 00:00:00

  • Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

    abstract::Amorolfine is a structurally unique, topically active antifungal agent, which possesses both fungistatic and fungicidal activity in vitro. Its spectrum of in vitro activity includes dermatophyte, dimorphic, some dematiaceous and filamentous fungi, and some yeasts. In clinical trials, application of amorolfine 5% nail ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549010-00008

    authors: Haria M,Bryson HM

    更新日期:1995-01-01 00:00:00

  • Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.

    abstract::Matrix metalloproteinases (MMPs) are a family of functionally related zinc-containing enzymes that denature and degrade fibrillar collagens and other components of the extracellular matrix. Myocardial extracellular matrix remodelling and fibrosis regulated by MMPs are believed to be important contributors to the progr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161090-00002

    authors: Li YY,Feldman AM

    更新日期:2001-01-01 00:00:00

  • Tenapanor: First Approval.

    abstract::The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01215-9

    authors: Markham A

    更新日期:2019-11-01 00:00:00

  • Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update.

    abstract::Lifestyle interventions constitute the initial strategy for the primary and secondary prevention of cardiovascular disease in women. However, pharmacotherapy is often indicated for control of major cardiovascular risk factors, and abundant clinical trial data support the morbidity and mortality benefit of a number of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868030-00006

    authors: Wenger NK

    更新日期:2008-01-01 00:00:00

  • Treatment of chronic schizophrenia.

    abstract::The comprehensive treatment of schizophrenia requires the full resources of a clinical team that is able to offer treatment for the acute psychotic state in a hospital environment, and appropriate rehabilitation following resolution of the florid symptoms. Following a second or subsequent relapse, maintenance therapy ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197714040-00004

    authors: Johnson DA

    更新日期:1977-10-01 00:00:00

  • The cost of treating systemic fungal infections.

    abstract::The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have been difficult to estim...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161001-00005

    authors: van Gool R

    更新日期:2001-01-01 00:00:00

  • Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.

    abstract::Utilising a modified fixed-dose, 4 x 3 factorial design, the antihypertensive effects of all combinations of 4 doses of pinacidil (0, 12.5, 25 and 37.5 mg bid) with 3 doses of hydrochlorothiazide (0, 12.5 and 25 mg bid) were studied in patients with supine diastolic blood pressure of 95 to 110mm Hg. The decreases in s...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800367-00015

    authors: Goldberg MR,Offen WW

    更新日期:1988-01-01 00:00:00

  • NSAIDs and gastrointestinal cancer prevention.

    abstract::Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointest...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262060-00006

    authors: Jolly K,Cheng KK,Langman MJ

    更新日期:2002-01-01 00:00:00

  • Management of cystitis in young women.

    abstract::The common clinical problem of recurrent symptomatic urinary tract infections (UTI) in young women may be inconvenient and distressing to both the patient and her family, particularly if the infections are not managed in a rational manner. A suggested approach is included in table 1. ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197713020-00003

    authors: Bailey RR

    更新日期:1977-02-01 00:00:00

  • White coat hypertension and related phenomena. A clinical approach.

    abstract::In this paper, several clinical problems associated with the diagnosis of hypertension are discussed. Blood pressure variability and reactivity are factors underlying the difficulties in the diagnosis of hypertension. These phenomena are interrelated and mixed. White coat hypertension (WCH), referring to the phenomeno...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300462-00017

    authors: Ocón-Pujadas J,Mora-Maciá J

    更新日期:1993-01-01 00:00:00

  • Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

    abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-018-1009-0

    authors: Chen BK,Yang YT,Bennett CL

    更新日期:2018-11-01 00:00:00

  • Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

    abstract::Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including cervical dystonia (CD) and benign essential blepharospasm (BEB). It is also known to relieve hemifacial spasm and focal spasticity in children and adults. In addition, BTX-A has been shown to...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767050-00003

    authors: Jost WH,Blümel J,Grafe S

    更新日期:2007-01-01 00:00:00

  • Anagrelide: a review of its use in the management of essential thrombocythaemia.

    abstract::Anagrelide (Agrylin, Xagrid) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of elevated platelet counts and t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666010-00006

    authors: Wagstaff AJ,Keating GM

    更新日期:2006-01-01 00:00:00

  • The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

    abstract::Tuberous sclerosis complex (TSC) is a genetic disorder arising from mutations in the TSC1 or TSC2 genes. The resulting over-activation of the mammalian target of rapamycin (mTOR) signalling pathway leaves patients with TSC susceptible to the growth of non-malignant tumours in multiple organs. Previously, surgery was t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0552-9

    authors: Curatolo P,Bjørnvold M,Dill PE,Ferreira JC,Feucht M,Hertzberg C,Jansen A,Jóźwiak S,Kingswood JC,Kotulska K,Macaya A,Moavero R,Nabbout R,Zonnenberg BA

    更新日期:2016-04-01 00:00:00

  • Pharmacological and biochemical actions of sulphasalazine.

    abstract::This review considers recent pharmacological and biochemical studies of sulphasalazine and its colonic metabolites, 5-aminosalicylic acid and sulphapyridine, in relation to the use of the parent drug for the treatment of ulcerative colitis and, more recently, rheumatoid arthritis. Several factors make it difficult to ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198600321-00005

    authors: Hoult JR

    更新日期:1986-01-01 00:00:00

  • Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

    abstract::Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin. It and other camptothecin analogues/derivatives appear to exert their antitumour activity by binding to topoisomerase I. The active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), has demonstrated potent growth inhibition of human col...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00013

    authors: Wiseman LR,Markham A

    更新日期:1996-10-01 00:00:00

  • Valsartan/hydrochlorothiazide.

    abstract::Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957050-00008

    authors: Langtry HD,McClellan KJ

    更新日期:1999-05-01 00:00:00

  • Dulaglutide: A Review in Type 2 Diabetes.

    abstract::Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01260-9

    authors: Scott LJ

    更新日期:2020-02-01 00:00:00

  • Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

    abstract::Mild to moderate hypertension still remains poorly controlled. This relates to multiple factors including low antihypertensive efficacy of single drug therapies reluctance of primary care physicians to modify/titrate initially chosen therapy to obtain target blood pressure, and poor compliance with medication. Several...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161070-00004

    authors: Ruzicka M,Leenen FH

    更新日期:2001-01-01 00:00:00

  • Pharmacotherapy for obesity.

    abstract::Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction, and has included thyroid hormone, amphetamines, phentermine, amfepramone (diethylpropion), phenylpropanolamine, mazindol, fenfluramines and, more recently, sibutramine and orlistat. These agents...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/00003495-200565100-00006

    authors: Ioannides-Demos LL,Proietto J,McNeil JJ

    更新日期:2005-01-01 00:00:00

  • Activity of quinolones against mycobacteria.

    abstract::The fluoroquinolones have been shown to be active in vitro against many mycobacterial species, including most strains of Mycobacterium tuberculosis complex and M. fortuitum, and some strains of M. kansasii, M. avium-intracellulare (MAI) complex and M. leprae. Ciprofloxacin, ofloxacin and sparfloxacin are the best stud...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958002-00004

    authors: Jacobs MR

    更新日期:1999-01-01 00:00:00

  • Peficitinib: First Global Approval.

    abstract::Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01131-y

    authors: Markham A,Keam SJ

    更新日期:2019-06-01 00:00:00

  • Traditional management of liver disorders.

    abstract::Dietary measures have achieved mixed results in the management of liver disorders. Although a high energy diet may shorten the course of viral hepatitis by a relatively small amount, dietary restriction is usually of no benefit in compensated cirrhosis. Restriction of sodium intake to 22 to 60 mol/day leads to resolut...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199000403-00005

    authors: Messner M,Brissot P

    更新日期:1990-01-01 00:00:00

  • Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

    abstract::Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the Helsinki Heart Study, these effec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651060-00009

    authors: Spencer CM,Barradell LB

    更新日期:1996-06-01 00:00:00

  • Management of restless legs syndrome in patients on dialysis.

    abstract::Restless legs syndrome (RLS) is characterised by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. RLS occurs in 3-15% of the general population and in 10-30% of patients on maintenance dialysis. RLS may lea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666050-00003

    authors: Molnar MZ,Novak M,Mucsi I

    更新日期:2006-01-01 00:00:00

  • Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.

    abstract::Vemurafenib is the first molecularly targeted therapy to be licensed in the US and Europe for treatment of advanced melanoma. Its mechanism of action involves selective inhibition of the mutated BRAF V600E kinase that leads to reduced signalling through the aberrant mitogen-activated protein kinase (MAPK) pathway. Its...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11640870-000000000-00000

    authors: Sharma A,Shah SR,Illum H,Dowell J

    更新日期:2012-12-03 00:00:00